Posted on by ScienceFather

Michel Hamon - Neuropharmacological research - Lifetime achievement Award

Professional Profiles:

scopus Profile

orcid Profile

researchgate Profile

Early Academic Pursuits:

His academic journey began at the prestigious Ecole Normale Supérieure (Ulm), where he was a student from 1966 to 1970. He earned his Maîtrise de Biologie Animale from the University of Paris in 1968, followed by a DEA de Biochimie in 1969 and an Agrégation de Physiologie-Biochimie in 1970. His academic pursuits culminated in a Thèse (PhD) de Doctorat es Sciences in the specialty of Neurosciences from the University of Paris VII in 1974.

Professional Endeavors:

His professional career at INSERM (Institut National de la Santé et de la Recherche Médicale) spans several decades, showcasing a progression from Research Assistant to Director of Research - Top class. His roles include significant periods as Director of Research at Unit 288 (Faculty of Medicine Pitié-Salpêtrière) and later as Professor of Neuropharmacology at the University Pierre & Marie Curie (UPMC). He continued his academic engagement as an Emeritus Professor at UPMC. His has also displayed leadership in laboratory management, founding and directing both INSERM Unit 288 and UMR 677 INSERM/UPMC, focusing on Molecular, Cellular, and Functional Neurobiology, as well as Neuropsychopharmacology.

Contributions and Research Focus:

Throughout his career, He has contributed significantly to preclinical research, with expertise in molecular neurobiology, cellular neurobiology, neurophysiology, neurochemistry, and neuropsychopharmacology. His research extended to behavioral studies using animal models, particularly rats and mice. His leadership in the field is evident through the establishment and direction of various research units, emphasizing the molecular and functional aspects of neurobiology. Notably, his work included the exploration of pain, stress, and neurovegetative adaptations.

Accolades and Recognition:

He has received numerous prizes and honors, including the Prize of Lacassagne Foundation, the Sterling Prize from the University of Pennsylvania, and the Paul Ehrlich Prize from the French Society of Medicinal Chemistry. He is recognized as an Associate Member of the National Academy of Medicine and the National Academy of Pharmacy. His contributions were further acknowledged with the ECNP Neuropsychopharmacoly Award in 2017, underlining his impact on the field.

Impact and Influence:

With an extensive publication record, including over 600 original papers and 250 review articles, His has established himself as one of the most frequently cited French scientists. His work has significantly impacted the scientific community, earning him a place among "Highly cited researchers." His leadership roles in scientific societies, editorial boards, and various committees reflect his influence on the broader scientific landscape.

Legacy and Future Contributions:

His legacy is characterized by his leadership, prolific research output, and impact on the field of neurobiology and neuropsychopharmacology. As an educator, he has shaped the next generation of scientists through teaching and mentoring.

Notable Publications:

1 Experimental neuropsychopharmacology, yesterday, today and tomorrow. A conversation with Michel Hamon Hamon, M., Zimmer, L. TherapiesThis link is disabled., 2021, 76(2), pp. 63–66 

2 Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment Martin, V., Mathieu, L., Diaz, J., ...Stockmeier, C.A., Masson, J. Journal of Psychiatry and NeuroscienceThis link is disabled., 2020, 45(5), pp. 344–355

3 Pharmaco-fUS for Characterizing Drugs for Alzheimer’s Disease – The Case of THN201, a Drug Combination of Donepezil Plus Mefloquine Vidal, B., Droguerre, M., Valdebenito, M., ...Mouthon, F., Charvériat, M. Frontiers in NeuroscienceThis link is disabled., 2020, (14) , 835

4 Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer’s DiseaseDroguerre, M., Duchêne, A., Picoli, C., ...Mouthon, F., Charvériat, M. Frontiers in NeuroscienceThis link is disabled., 2020, (14) , 563

5 A New Tool for In Vivo Study of Astrocyte Connexin 43 in BrainDroguerre, M., Tsurugizawa, T., Duchêne, A., ...Ciobanu, L., Charvériat, M. Scientific ReportsThis link is disabled., 2019,  (12), 18292

6 A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphineFeng, J., Lepetre-Mouelhi, S., Gautier, A., ...Hamon, M., Couvreur, P. Science Advances, 2019, (56), eaau5148

7 The GABAergic Gudden's dorsal tegmental nucleus: A new relay for serotonergic regulation of sleep-wake behavior in the mouseChazalon, M., Dumas, S., Bernard, J.-F., ...Fabre, V., Bonnavion, P. NeuropharmacologyThis link is disabled., 2018, (5) 138, pp. 315–330

8 α2- and β2-adrenoreceptor-mediated efficacy of the atypical antidepressant agomelatine combined with gabapentin to suppress allodynia in neuropathic rats with ligated infraorbital or sciatic nerveM'Dahoma, S., Poitevin, M., Dabala, E., ...Bourgoin, S., Hamon, M. Frontiers in PharmacologyThis link is disabled., 2018, (6) 9(JUN), 587

9 Differential innervation of superficial versus deep laminae of the dorsal horn by bulbo-spinal serotonergic pathways in the ratGautier, A., Geny, D., Bourgoin, S., Bernard, J.F., Hamon, M. IBRO Reports, 2017, (10), pp. 72–80

10  Yin and yang in serotonin: Its Janus roles in pain control mechanisms | Le yin et le yang de la sérotonine : un Janus dans les contrôles de la douleurBourgoin, S., Gautier, A., Hamon, M. Douleur et AnalgesieThis link is disabled., 2017, 30 (1), pp. 35–56

Michel Hamon | Neuropharmacological research | Lifetime achievement Award

You May Also Like